Clinical Report: A Systemic Problem in Metabolite Identification?
Overview
A significant misidentification of phenylacetylglutamine (PAGln) as phenylacetylglycine (PAGly) has been found in nearly half of NMR-based studies involving human urine samples over the past few decades. This persistent error raises concerns about the reliability of metabolomic data and its implications for clinical interpretations.
Background
Accurate metabolite identification is crucial for understanding metabolic pathways and their clinical relevance, especially as metabolites like PAGln are linked to various cardiovascular and neurological diseases. The propagation of misidentifications undermines the credibility of metabolomics, potentially leading to incorrect biological interpretations and clinical decisions. Addressing these errors is essential for advancing the field and ensuring the validity of research findings.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
['Nearly 49% of NMR-based studies misidentified PAGln as PAGly in human urine samples.', 'The misidentification is attributed to reliance on overlapping spectral signals in NMR analysis.', 'PAGln is unique to humans, while PAGly is found only in rodents due to species-specific metabolic pathways.', 'Errors in metabolite assignment extend beyond PAGln and PAGly, indicating a broader issue in metabolomics.', 'Correct metabolite identification is critical as PAGln is associated with cardiovascular risk in humans.']Clinical Implications
Clinicians and researchers should be aware of the potential for misidentification in metabolomic studies, particularly those relying on NMR techniques. Ensuring accurate metabolite assignments is vital for interpreting clinical data and understanding disease mechanisms. The findings underscore the need for improved identification workflows in metabolomics to enhance the reliability of research outcomes.
Conclusion
The systematic misidentification of metabolites like PAGln poses significant challenges for the metabolomics field. Addressing these issues is essential for maintaining the integrity of research and its clinical applications.
References
- Nicholson et al., Analytical Chemistry, 2025 -- Investigating a Systematic and Widespread Misidentification in the Metabolic Profiling Literature: Phenylacetylglutamine and Phenylacetylglycine Signal Misassignment in Proton NMR Spectra of Human and Rodent Urine
- Giera et al., European Heart Journal, 2025 -- Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions
- Halama et al., Archives of Toxicology, 2022 -- Utilizing Metabolic Profiling to Investigate Cellular Changes Induced by 20 Mycotoxins in HepG2 Cell Lines
- Bujak et al., Archives of Toxicology, 2021 -- Metabolomic Profiling for Differentiating Phenotypes of Drug-Induced Liver Injury (DILI)
- the analytical scientist — The Missing Piece in the Dark Metabolome Puzzle?
- Archives of Toxicology — Utilizing In Silico Tools to Identify Metabolites of Emerging Psychoactive Compounds
- The Missing Piece in the Dark Metabolome Puzzle?
- Investigating a Systematic and Widespread Misidentification in the Metabolic Profiling Literature: Phenylacetylglutamine and Phenylacetylglycine Signal Misassignment in Proton NMR Spectra of Human and Rodent Urine | Analytical Chemistry
- Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions | European Heart Journal | Oxford Academic
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
